COVID-19: A Global health concern

COVID-19 IgM/IgG Rapid Antibody Test Kit


Fast detection of COVID-19

The test can be performed in 10 minutes from patients' whole blood, serum or plasma.

Suitable for testing a large number of patients

Due to its simplicity and minimal sample preparation time, this kit can be used for screening a larger number of people.

Affordable testing expenses

Since highly trained personnel or expensive equipment is not needed, the cost of testing is relatively low.

Certified Quality Standards

Manufactured under ISO13485:2016, received CE Mark and provisional authorisation from Health Sciences Authority (Singapore).

COVID-19 Viral Antigen Test Kit


Early diagnosis

The kit is able to detect the infection at the early stages, when only viral particles are present, but no virus-specific antibodies are present yet.

Highly specific

Less chance for cross-reactivity with other types of flu viruses.

Easy to use

Only a simple throat swab is needed and the diagnosis is ready within 20 minutes.

Highly sensitive

We provide a UV pen flashlight that enhances the evaluation of results from the fluorescent assay.



COVID-19 Neutralizing Antibody Test


Rapid detection of COVID-19 Immune individuals

The test can be used to identify people who have developed immunity against COVID-19.

Suitable for issuing Immunity Passports

The detection of neutralizing antibodies from the blood of recovered patients gives better confidence regarding immunity than IgM/IgG based tests.

Affordable testing expenses

Since highly trained personnel or expensive equipment is not needed, the cost of testing is relatively low.

Easy to use format

The neutralizing antibody test is typically done in laboratory assay format. We have developed a convenient rapid test kit for this purpose.

ProTect™ COVID-19 RT-qPCR Kit

by JN Medsys

All-in-One

The kit provides all the necessary reagents for the in vitro qualitative detection of the COVID-19 virus from respiratory specimens and serum samples.

Tested and reliable protocol

The kit is compatible with the US CDC protocol and received provisional authorisation from Health Sciences Authority (Singapore).

Early detection

The amplification of viral nucleic acids provides detection at very early stages of the infection, even before symptoms occur.

Wide range of suitable samples

Viral particles are present in the throat and sputum. Nasopharingeal swabs make it easy to acquire specimens.



Specimen Collection Kit

by JN Medsys

Intended use

For the collection of cells and microbiological specimen from the nasopharyngeal area, followed by storage in the medium for transport to the laboratory for analysis.

Contents of the kit

1 x flocked swab and 1 x viral universal transport medium (2ml)
100 per pack

Extended shelf life

The collection kit aan be stored at 15-30ºC for 12 months.

For COVID-19 Screening

This samples collection kit includes the basic components that is needed for collecting nasopharyngeal swabs for RT-qPCR analysis to determine SARS-CoV-2 infection.

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibodies


Specific antibodies against viral Spike protein

These developed antibodies interact with the Spike protein of SARS Coronavirus and SARS Coronavirus 2 (COVID-19).

Wide range of research applications

The mouse monoclonal antibodies can be used on Western blot, FACS, Immunoprecipitation, ELISA and other laboratory applications.

Several antibody types available

We offer three different IgG types of antibodies with distinct binding profiles, which all have been independently verified.

Certified Quality Standards

High purity antibodies, which can be delivered in customized volume and format (lyophilized, PBS).

Why is testing important?


We want to know the total number of people infected with COVID-19. To know this, it is necessary to have widespread testing.

When testing is too low we do not have a clear picture of what is going on.

Testing is crucial as it allows the infected person to avoid infecting others and to quickly receive the care they need. And it is crucial for all of us to understand the prevalence of the disease, to understand how the disease evolves, and to allow us to take evidence-based decisions for counter measures that slow down the spread of the disease.

Source: https://ourworldindata.org/coronavirus

Research partnerships


Camtech™ works together with A*STAR, Singapore's Agency for Science, Technology and Research, in developing more specific and targetted antibody tests for IgM/IgG.

Frequently asked questions


There are several approaches that can be used to identify an infection, these focus on detecting either viral proteins (Early detection), viral nucleotide sequences (Early detection) or antibodies (Later detection) raised against specific viral components.

  1. Quantitative Polymerase Chain Reaction (qPCR) is used for detecting specific nucleotide sequences of the virus. These nucleotide sequences encode proteins that are crucial for the virus to hijack cellular mechanisms to drive the production of new viral particles. These nucleotide sequences can be isolated and amplified using PCR, and further quantified using fluorescent probes using qPCR systems.

  2. Enzyme-linked immunosorbent assays (ELISAs) provide a readout of antigen-antibody interactions.
    In the case of IgM/IgG antibody tests, patient antibodies are “sandwiched” between the deposited viral protein of interest and reporter antibodies, so that any active patient antibodies are detected.
    Antigen tests work similarly, but in that case the Antigen-specific capture antibody is deposited and the viral particles get captured between this and the labelled antigen-specific antibody. The labeling method can produce a visible signal (immunogold) or a fluorescent signal, that is revealed under UV-light. Rapid test kits, or Lateral Flow Assays (LFA) are based on the same principles, but are packaged into an easy to use, point-of-care format.

  3. Neutralization tests can indicate whether the patient has active, functional antibodies to the pathogen in question by measuring how much the patient antibodies can inhibit viral growth in the lab.

The WHO has recommended countries implement more widespread testing. You should check with your local healthcare provider if COVID-19 testing is available in your area. Although an increase in testing volumes may result in delays or lack of availability for milder cases.

The incubation period for the infection can vary from 2 to 14 days. This variation makes it difficult to pinpoint a timeframe when a person was infected and could vary by the same amount as the incubation period.

Patient antibodies (IgM/IgG) against the virus particles, which is tested by the COVID-19 IgM/IgG Rapid test kit, only appear after symptoms arise (1-3 weeks). The recommended time frame is 7 days after the onset of symptoms (87% Sensitivity), when IgMs and IgGs can be visually detected using the LFA kit. However, sensitivity improves over time and is over 95% 10 days post symptoms. Antigen Rapid test or RT-qPCR test is recommended to identify acute COVID-19.

The COVID-19 Viral Antigen Detection kit detects the Nucleocapsid (N) protein of the SARS-CoV-2 virus from naso- or oropharyngeal swabs, while the ProTect™ COVID-19 RT-qPCR kit is based on the direct molecular diagnostics of the virus RNA. Based on other respiratory viral infections it is estimated that the detectable viral load is present after 3-4 days of infection, which typically coincides with the first few days of the onset of symptoms. Rapid antigen test kits can reliably identify patients with high viral load during the first 7 days after the onset of symptoms, while the RT-PCR test can still detect viral RNA for an extended period of time (2-3 weeks after infection).

Please refer to the individual brochures for accuracy information.
Please get in touch with us through the Contact form indicating the type and volume of the testing kits needed.
The Camtech™ COVID-19 IgM/IgG test has been designed to minimise the likelihood of false positive test results. With regards to serological testing the FDA specifies that true negative samples should have been from patients prior to the SARS-CoV-2 outbreak (pre-pandemic samples) as RT-qPCR is not an effective way of ruling out past infections. However, If the Camtech™ IgM/IgG test gives you a positive result which is in contrast with a negative RT-qPCR result there may be several factors to consider, these include but are not limited to.

  • RT-qPCR may be negative due to the lack of viral nucleotides in patients who have recovered from SARS-CoV-2, however, antibodies against the infection may persist, resulting in a positive Antibody test.

  • Cross-reactivity with non- SARS-CoV-2 associated circulating antibodies (i.e. Influenza).

  • The RT-qPCR result may be a false negative.

  • Poor interpretation of results, potentially due to use by non-qualified medical professionals.
Positive antigen kit result: If you have a positive result it is very likely that you have the proteins from the virus that was found in your sample. The antigens are generally detectable in the specimens from the upper respiratory tract, nevertheless, clinical correlation with patient history and the necessary diagnostic information is required to determine the infection status. Positive results also do not rule out bacterial infection or cross-infections with other bacteria or viruses.

Negative antigen kit result: A negative result indicates that the antigens from SARS-CoV-2 was not present in the specimen. It also means that the viral load was below the limit of detection. The amount of antigen in a sample is known to decrease with the increase in the duration of the illness. However, a negative test should not be used as the only basis of treatment or patient management as samples collected beyond 7 days post symptom should be treated as presumptive and confirmed with a molecular assay.

Technical information


  • All Camtech™ tests kits are manufactured under ISO 13485.

  • Both the COVID-19 Viral Antigen Detection Kit and the COVID-19 IgM/IgG Rapid Antibody Test Kit have obtained provisional authorisation from the Singapore Health Sciences Authority (HSA), have been approved by the Philippine FDA and received a Declaration of conformity from the EU (CE IVD).

  • The ProTect™ COVID-19 RT-qPCR Kit has obtained provisional authorisation from the Singapore Health Sciences Authority (HSA) and has a declaration of conformity from the EU (CE IVD).

  • Please note that our products are not to be used by consumers or marketed over the counter or directly to consumers and are only for use by certified healthcare establishments or where administered by a trained healthcare professional and in accordance to the "Instructions for Use" of the product.

  • Results from the rapid test kits should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status, particularly in those who have been in contact with virus carriers. Follow-up testing with a molecular diagnostic method should be considered to rule out infection in these individuals.

  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

  • Not for the screening of donated blood.


Contact Us


  • If you are a healthcare establishment or professional and would like to order a box of sample kits for evaluation, you may order on this website. Sample kits for evaluation are sold as a box of 20. You will need to provide the details of your healthcare establishment or practitioner details in order to purchase.

  • For larger orders, we have a Minimum Order Quantity. For such enquiries, please contact us on the form below.

  • If you are a hospital/ clinical research institute and would like to undertake a research collaboration on infected patient samples kindly reach us below with your project description.

Camtech™ Privacy Policy